A clinical trial of intraperitoneal pretreatment with bortezomib prior to the intraperitoneal administration of carboplatin in patients with ovarian cancer, directed at preventing carboplatin-induced CTR1 downregulation, has just been opened. Here, CALCR is linked to ovarian carcinoma.